Novartis (NVS)
(Delayed Data from NYSE)
$118.50 USD
-2.39 (-1.98%)
Updated Sep 3, 2024 04:00 PM ET
After-Market: $118.50 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$118.50 USD
-2.39 (-1.98%)
Updated Sep 3, 2024 04:00 PM ET
After-Market: $118.50 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth D Momentum D VGM
Zacks News
What's in the Cards for Intellia (NTLA) This Earnings Season?
by Zacks Equity Research
Intellia Therapeutics (NTLA) is likely to discuss the progress of its pipeline candidate on its fourth-quarter earnings call.
The Zacks Analyst Blog Highlights: AstraZeneca, Eli Lilly, Sanofi, GlaxoSmithKline and Novartis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AstraZeneca, Eli Lilly, Sanofi, GlaxoSmithKline and Novartis
Alnylam's (ALNY) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Alnylam (ALNY) reported a wider-than-expected loss but revenues beat estimates in the fourth quarter of 2020.
Pharma Stock Roundup: AZN's Q4 Earnings, FDA Approval for LLY & SNY's Drugs
by Kinjel Shah
AstraZeneca (AZN) announces Q4 results. FDA approves Lilly's COVID-19 antibody cocktail & Sanofi's (SNY) Libtayo for a new indication.
Novartis (NVS) Gets Breakthrough Therapy Tag for Leukemia Drug
by Zacks Equity Research
Novartis' (NVS) asciminib gets Breakthrough Therapy tag by the FDA for the treatment of adult patients with Ph+ CML in chronic phase, previously treated with two or more tyrosine kinase inhibitors.
Bristol Myers (BMY) Gets FDA Approval for CAR T-Cell Therapy
by Zacks Equity Research
Bristol Myers (BMY) obtains FDA approval of CAR T cell therapy, Breyanzi, for the treatment of lymphoma.
Roche (RHHBY) 2020 Earnings Down Due to Biosimilars, COVID-19
by Zacks Equity Research
Roche's (RHHBY) performance in 2020 gets negatively impacted by biosimilar competition and coronavirus-related disruptions. Nevertheless, the diagnostics division maintains momentum.
Regeneron (REGN) Q4 Earnings, Sales Beat on Solid Dupixent Show
by Zacks Equity Research
Regeneron (REGN) beats on Q4 earnings and sales on solid performance of Dupixent, Eylea and incremental contribution from oncology drug, Libtayo.
Incyte (INCY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are likely to focus on pipeline updates besides top and bottom-line numbers when Incyte (INCY) reports fourth-quarter 2020 results.
Pharma Stock Roundup: JNJ, NVS Q4 Earnings, MRK & LLY's Coronavirus Updates
by Kinjel Shah
J&J (JNJ) and Novartis (NVS) announce Q4 results. Merck (MRK), AbbVie (ABBV) & Pfizer (PFE) get EU approvals.
Will Glaxo (GSK) Q4 Earnings Recover From Coronavirus Woes?
by Zacks Equity Research
Glaxo's (GSK) new and specialty products are likely to have driven fourth-quarter sales. The results will provide clarity on the impact of coronavirus on the company's vaccine business.
Novartis (NVS) Misses on Q4 Earnings, Issues Grim 2021 Outlook
by Zacks Equity Research
Novartis (NVS) reports dismal fourth-quarter results as the pandemic affected sales. The outlook for 2021 also indicates challenges ahead.
Incyte's (INCY) BLA for Cancer Drug Accepted for Priority Review
by Zacks Equity Research
Incyte's (INCY) application for pipeline candidate, retifanlimab, for adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal (SCAC) gets Priority Review.
Regional Banks Post Mixed Earnings Results
by Zacks Equity Research
Regional Banks Post Mixed Earnings Results.
Q4 Earnings Come to Regional Banks: ALLY, HBAN & More
by Mark Vickery
Most of the Big Banks have already posted for Q4; this morning we see a large share of Regional Banks reporting quarterly earnings.
Merck's (MRK) Heart Failure Drug Vericiguat Gets FDA Nod
by Zacks Equity Research
Merck (MRK)/Bayer's (BAYRY) vericiguat gets FDA approval for symptomatic chronic heart failure and reduced ejection fraction
Roche's (RHHBY) Esbriet sNDA Gets Priority Review From FDA
by Zacks Equity Research
The FDA accepts Roche's (RHHBY) sNDA for Esbriet under a priority review to treat unclassifiable interstitial lung disease. A verdict from the regulatory body is awaited in May 2021.
The Zacks Analyst Blog Highlights: Novartis, QUALCOMM, Accenture, MetLife and Electronic Arts
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novartis, QUALCOMM, Accenture, MetLife and Electronic Arts
Top Stock Reports for Novartis, QUALCOMM & Accenture
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novartis (NVS), QUALCOMM (QCOM), and Accenture (ACN).
BeiGene (BGNE) Up on Label Expansion of Tislelizumab in China
by Zacks Equity Research
BeiGene (BGNE) gains following the approval of tislelizumab for the lucrative indication of advanced squamous non-small cell lung cancer in China.
Novartis' (NVS) Ligelizumab Gets Breakthrough Therapy Status
by Zacks Equity Research
Novartis (NVS) gets Breakthrough Therapy designation by the FDA for ligelizumab for the treatment of chronic spontaneous urticaria.
Pharma Stock Roundup: LLY's Alzheimer Disease Data, NVS & SNY's M&A Deals
by Kinjel Shah
Lilly's (LLY) candidate, donanemab shows slowing of cognitive decline in Alzheimer's disease patients. Novartis (NVS) and Sanofi (SNY) announce M&A deals.
Alexion (ALXN) to Pause Enrollment in COVID-19 Study on Ultomiris
by Zacks Equity Research
Alexion (ALXN) decides to stop further enrollment in the late-stage study of Ultomiris in adults with severe COVID-19 requiring mechanical ventilation due to lack of efficacy.
Novartis (NVS) In-Licenses Anti-PD-1 Antibody from BeiGene
by Zacks Equity Research
Novartis (NVS) in-licenses BeiGene's anti-PD-1 monoclonal antibody, tislelizumab, in major markets outside of China.
AbbVie's (ABBV) Skyrizi Succeeds in Crohn's Disease Studies
by Zacks Equity Research
AbbVie's (ABBV) Skyrizi achieves improvements in clinical remission and endoscopic response in phase III studies in moderate to severe Crohn's disease patients.